

出國報告(出國類別：開會)

臨床微生物檢驗自動化系統及發展趨勢

服務機關：國防醫學院三軍總醫院

姓名職稱：闕宗熙 上校與 孫俊仁 少校

派赴國家：西班牙

報告日期：103 年 5 月 19 日

出國時間：103 年 5 月 8 日至 5 月 14 日

壹、摘要

本次關宗熙 上校主任與孫俊仁獲邀參加 24 屆歐洲臨床微生物及感染症大會 (ECCMID)。本次會議地點為西班牙巴賽隆納。時間為 103 年 5 月 8 日至 5 月 14 日，為期四天。在期間，我們除了參與發表壁報論文外亦參加多個會議學習微生物檢驗新知，此行成果相當豐碩。吾人相關學習成果簡述如下：1. 發表兩篇電子壁報 (編號: eP508 與 eP509) 分享三總研究成果：此次發表兩篇鮑氏不動桿菌 (*Acinetobacter baumannii*) 相關抗藥機轉研究之壁報。2. 參與多個基礎與臨床會議吸收臨床微生物檢驗新知：未來相關新知將會嘗試應用於臨床微生物檢驗。3. 臨床細菌檢驗自動化與發展趨勢議題的深入了解。全自動化微生物實驗室在近年來有日趨成型的趨勢。本次會議亦針對微生物實驗室自動化開設一系列專題討論與現場實機展覽，吾人亦針對該主題進行深入瞭解與學習。

目次:

| | |
|--|--------|
| 壹、摘要..... | (2) |
| 貳、本文..... | (3) |
| 一、目的..... | (3) |
| 二、過程..... | (4) |
| 三、心得與建議..... | (10) |
| 參、附件..... | (12) |
| 附件一、24屆歐洲臨床微生物及感染症大會(ECCMID)會議議程..... | (12) |
| 附件二、與會人員與ECCMID陳設之中華民國國旗合照..... | (17) |
| 附件三、與會人員與三總在本次ECCMID會場發表之電子壁報合照..... | (18) |
| 附件四、關宗熙主任與孫俊仁發表壁報列於大會手冊..... | (19) |
| 附件五、全自動化微生物實驗室 | (20) |
| 附件六、Kiestra TLA system全自動化微生物實驗室陳設於ECCMID會場 | (21) |

貳、本文

一、目的:

臨床服務、教學與研究是醫學中心的三大要素。三者相輔相成，缺一不可。闕宗熙上校主任與孫俊仁藉由本次參加 24 屆歐洲臨床微生物及感染症大會 (ECCMID)與世界各大醫學中心與研究機構進行研究交流。在這四天的議程中，除了展現三軍總醫院在微生物感染症的相關研究成果外，亦可以觀摩其他學者的研究成果並且學習其他微生物檢驗的新穎知識與最新發展。參加本屆會議主要目的有三:

第一、發表兩篇壁報展現三總研究成果: 闕宗熙上校主任與孫俊仁研究主軸為探討鮑氏不動桿菌 (*Acinetobacter baumannii*; 簡稱 AB)相關抗藥機轉研究，此次發表之兩篇壁報為本實驗室在鮑氏不動桿菌抗藥機轉的最新研究成果。

第二、吸收臨床微生物檢驗相關新知: 本次大會安排多個不同的感染症相關主題進行研究探討，其中包含臨床與基礎等相關研究與最新檢驗技術。闕宗熙上校主任與孫俊仁藉由參加此次大會而有學習許多臨床微生物檢驗之新穎知識，未來希望能應用於臨床服務或教學研究方面。

第三、深入了解相關臨床細菌檢驗自動化與發展趨勢: 未來在面對與日俱增的臨床檢驗量與檢驗複雜性，實驗室檢驗自動化是未來的趨勢。目前，臨床生化檢驗部分已經有許多醫院導入自動軌道系統幫助讓檢驗流程順暢與增加服務品質。但是，臨床微生物檢驗是一個必須仰賴高度人力與經驗的檢驗工作，培育人才不亦且工作內容耗時繁雜。本次大會安排相關主題探討自動化在未來微生物檢驗的可能性與其扮演的角色，並且有多位學者分享相關實驗室自動化之規畫經驗。闕宗熙上校主任與孫俊仁藉由本次會議習得相關知識作為未來臨床微生物實驗室進行自動化規劃之參考依據。

二、過程:

本次參加 24 屆歐洲臨床微生物及感染症大會(ECCMID)會議，會議地點為西班牙巴塞隆納市的巴塞隆納國際會議中心。大會會議議程為四天，相關議程參照附件一。

103.05.10 行程:

當日上午關宗熙上校與孫俊仁約 8:00 於巴塞隆納國際會議中心辦理報到領取相關手冊資料，並與會場中華民國國旗合照留念（參照附件二）。根據出發前會議主辦單位發布的網路資訊與現場手冊資料得知：每天會場共有 11 個不同的會議室進行不同主題的教育訓練與口頭論文發表。而在壁報發表上可以區分兩種，其一為現場貼的論文壁報 (poster)及以觸控螢幕發表的電子壁報 (e-poster)。本日學習的相關議程如下:

1. **黴菌與細菌生物膜 (biofilm)之檢驗與治療:** 生物膜的成份是微生物所分泌的蛋白質與醣類附著於物質表面所形成的特殊結構。生物膜存在的主要目的為包覆於致病菌外圍保護致病菌可以抵禦免疫反應，而在生物膜內部進行複製生長的功用。然而，當細菌或是黴菌感染人體，約有 60-80%的致病菌會形成生物膜。致病菌形成生物膜會造成微生物感染症持續發生且抗生素或相關藥物因被生物膜所阻隔而不易直接作用到菌體。在本次會議中，特別請在這方面的專家針對生物膜的檢驗與治療進行深入探討與介紹。臨床微生物實驗室可以檢測自病人體內分離出的菌株是否會形成生物膜，主要可以檢驗可以分成三個階段: 1. 檢體採集。 2. 鑑定生物膜生成。 3. 生物膜定量。其中最難的部分為檢體採集: 直接自病人發炎患處採集檢體並進行相關染色觀察是否有生物膜之形成。在此階段遭遇的問題為須進行檢體採集的位置多半為混雜膿瘍與紅腫發炎，所以無法肉眼分辨是否為有細菌存在之病灶處。因此在檢驗上頗為困難並且目前沒有標準化的流程可以建議如何操作。檢體在經過採集後必須藉由超音波進行生物膜結構破壞讓內部細菌釋放出來，值得注意的是相關專家學者表示實驗室如果只是使用震盪器進行震盪則無法有效分離取得標本。接續為介紹致病菌形成生物膜的治療策略，一般微生物形成生物膜上可以區分為數個時期: 第一階段為細菌的附著蛋白尚未附著於物體表面: 專家學者認為在此時可以利用針對細菌附著蛋白專一性的抗體與細菌的附著蛋白結合進而阻止細菌附著於

物體表面。第二階段為細菌已經附著於表面，則可以在細菌進行複製生長產生群聚或生物膜剛形成時使用藥物進行抑制生物膜的生成。如果到達最後階段已經完成生物膜生成階段，則相關抗生素或藥物將無法進行有效治療。會中提及可以利用奈米技術或與塗料將器械或導管表面進行處理，讓細菌無法附著就無法形成生物膜。此外亦有學者指出經過體外實驗發現可以利用一些天然植物萃取液去抑制生物膜的合成，甚至可以搭配抗生素的使用達到治療效力提升。未來此萃取物質可能可以應用於臨床治療相關會產生生物膜附著之細菌。

2. **厭氧菌 (anaerobe)檢驗的最新技術:** 厭氧菌的檢驗因為生長環境嚴苛必須是無氧環境才能生長，而臨床檢驗的鑑定技術並不如嗜氧菌鑑定技術發展成熟。本次大會亦特別邀請厭氧檢驗的專家進行相關鑑定技術的介紹。專家們都提及厭氧菌在臨床檢驗的難度除了難以培養外，還可能出現相同菌種但是菌種大小菌株不同，這時無法利用常規的生化鑑定方法進行區分是否為相同一株的厭氧菌。學者們藉由基因定序及其他生物技術證明厭氧菌種個菌株間有亞型的存在。基質輔助激光解吸電離飛行時間質譜 (Matrix-Assisted Laser Desorption/ Ionization Time of Flight Mass Spectrometry; MALDI-TOF)在近年來逐漸應用於臨床微生物實驗室，其主要是應用於細菌菌種鑑定。所以，會中有學者介紹利用該方法進行厭氧菌之菌種鑑定。唯目前相關厭氧菌的資料庫尚未齊全，所以在臨床真正應用上還有一段距離。厭氧菌藥物敏感度試驗在這次會議中提及近年來也可以提供最低抑菌濃度 (minimum inhibitory concentration; MIC)報告，但是要注意細菌用量會影響結果與其結果變異性較大的問題。

3. **電子壁報 (e-poster)發表:** 臨床病理科實驗室今年在 ECCMID 有兩篇關於鮑氏不動桿菌抗藥機轉的 e-poster 於上午 9:00 發表 (發表人與電子壁報合照請參照附件三)。其他研究學者於會場可以利用 LED 螢幕查閱相關研究成果並且利用線上提問系統詢問作者問題，作者亦可以利用該線上系統進行即時回答。闕宗熙主任發表主題為「AdeR protein regulates AdeABC expression by binding to direct-repeat motif in the intergenic spacer」，編號為 eP509。孫俊仁發表主題為「Verification of the amino acid substitutions in adeRS for tigecycline resistance in clinical isolates of the extensively drug resistant Acinetobacter

baumannii」，編號為 eP508。相關資料可以在大會手冊 (附件四)與由當日 LED 螢幕查詢到並且可以利用 App 系統看到摘要。

103.05.11 行程:

本日主要是學習重點為 MALDI-TOF 在臨床微生物實驗室的進階應用與鮑氏不動桿菌近期的相關研究成果

- MALDI-TOF 在臨床實驗室的應用:** 近年來，台灣各醫學中心紛紛引進 MALDI-TOF 進行相關致病菌菌種鑑定，希望藉此取代傳統生化鑑定。這方法具有快速鑑定與高準確性的特性，而且顛覆以往細菌鑑定流程。三軍總醫院細菌組在闕宗熙上校主任的指示下也引進一台 MALDI-TOF，期望利用該儀器提供更好的臨床服務。本次學者提及 MALDI-TOF 在目前鑑定流程上可以帶來的便利性外，還需要注意下列幾點: 1. 有些菌株因為 MALDI-TOF 圖譜較為接近所以在菌種的鑑別度較差，因此必須建立一套流程管制這些菌種報告的發放。 2. 因為 MALDI-TOF 在微生物鑑定上具有優越的性能，所以有學者開始希望利用其找尋抗藥性細菌的圖譜，但是，目前這方面的成果還在研究階段所以不可以作為臨床服務之用。 3. 以往微生物實驗室必須藉由許多生化反應才可以鑑別菌種，現在只需要以 MALDI-TOF 即可獲的相當準確的報告。但是，學者也擔心臨床醫檢師會因此荒廢了傳統生化鑑定技術，因此建議臨床微生物實驗室可以採用每月 1-2 天鑑定採用傳統生化鑑定以讓相關人員保有相關生化鑑定技術。
- 多重抗藥鮑氏不動桿菌抗藥機轉:** 在醫院所分離到的鮑氏不動桿菌因常具備多種抗生素的抗藥性與容易造成院內感染的特性，所以一直是臨床微生物實驗室的研究焦點。吾人本次於大會中發表的研究成果亦為針對鮑氏不動桿菌對老虎黴素 (tigecycline) 的抗藥機轉進行相關研究。本次大會於今日有一個講堂針對多重抗藥鮑氏不動桿菌最新抗藥機轉相關研究進行討論。其中會議中提及重點如下: 1. 學者利用全基因體定序(whole genome sequencing)嘗試了解鮑氏不動桿菌高抗藥性的特性，結果發現許多基因片段可能與高抗藥性有關。目前還需要更多實驗進行證實。 2. 其中有一學者與吾人研究主題相仿，同為研究老虎黴素抗藥機轉。該學者發現 AdeR 蛋白在 20 AA 位置進行改變將會影響 AdeABC

幫浦系統的表現進而影響抗藥性。這位點是目前尚未證實的地方與吾人實驗室目前的發現區間有所雷同，未來將可以進一步證實。

3. **參觀壁報展與 e-poster:** 參觀壁報展學習其他實驗室的最新研究與成果分享。

103.05.12 行程:

1. **全自動化微生物實驗室:** 微生物實驗室任務為致病菌種鑑定與藥物敏感度室驗報告的提供，因為所有流程皆須手工操作而較為繁忙。因此，實驗室自動化一直是微生物實驗室的夢想。近年來，隨著科技的進步，微生物實驗室的自動化日趨成型。本日亦有一專題報告為針對微生物實驗室自動化進行討論，其中會議中提及重點如下: 1. 全自動微生物實驗室共有三家廠商在進行相關模組開發，分別為 Kiestra TLA (BD Kiestra B.V., Drachten, Netherlands)、 full microbiology laboratory automation (FMLA; bioMérieux, Inc., La Balme, France) 及 WASPLab (Copan Diagnostics, Murrieta, CA)。相關系統圖片附於**附件五**。細部設計可以區分為自動抹片與自動接種、利用軌道系統進行接種完的培養皿運送、自動溫箱培養及定時偵測與利用影像系統進行初步判讀與後續鑑定。 2. 接種系統: 臨床檢體接種方式可以區分為使用傳統接種環 (loop)或是微量滴管尖 (tip)進行接種。後續塗抹部分也是可以區分為利用滾珠方式、橫桿或是接種環塗抹開來。 3. 軌道系統: 系統藉由電腦連線控制藉由軌道系統運送接種完的培養皿至溫箱與自動定時判讀。 4. 學者們分享相關實驗室規劃過程，希望實驗室利用此系統可以減輕實驗室人力負荷。因為需要鋪設軌道系統等設施，所以空間設計的考慮必須有獨立方正空間較佳而且會比目前實驗室空間為大。 5. 學者亦分享自動化系統建置上必須考慮除了相關系統工程建置部分還有後續維修能力，當系統出現問題必須有手工培養鑑定系統可以隨時替補，臨床服務才不會中斷。
2. **抗毒性藥物 (anti-virulence drug)的發展:** 隨著細菌的抗藥性日趨嚴重，抗生素的研發在近年來更是不斷推陳出新。除了新型態抗生素的問世外，還有一些抗生素是老藥新用。但是，抗生素的發展速度還是趕不上細菌抗藥性增加的速度。本次大會亦有一專題為報告目前抗毒性藥物的最新發展，會議中提及重點如下: 1. 有學者利用篩選出對抗綠膿桿

菌的單株抗體，該單株抗體可以中和細菌的毒力因子。而使毒力下降，在後續的細胞毒殺試驗中可以發現該單株抗體可以有效中和細菌毒性，未來菌有發展潛力。2. 另外有學者發現利用糖化合物 (carbohydrate)可以中和 *B. bronchiseptica* 的細胞壁而使其進行兔子感染實驗發現兔子發炎反應與死亡率下降。3. 另外有學者分享利用對抗 *E.coli* 的附著蛋白來抑制 *E.coli* 附著於尿道造成感染，這也是具有後續發展可能性。

3. 參觀壁報展與 e-poster: 參觀壁報展學習其他實驗室的最新研究

103.05.13 行程:

1. **參觀全自動化微生物實驗室設施:** 會場中有廠商實際將自動化微生物實驗室設施放置於會場，讓人實際感受該系統的新穎。闕宗熙上校與孫俊仁亦參觀了解並聽取廠商簡介。相關資料如附件六。
2. **參觀壁報展與 e-poster:** 參觀壁報展學習其他實驗室的最新研究

三、心得與建議

本次參加歐洲臨床微生物及感染症大會，收穫甚豐。針對參與盛會所獲得之心得如下：

1. **會議議程與動線設計順暢創新:** 在出發前往西班牙前，所有與會者都會收到一封大會寄送 e-mail。信件內容有一段條碼並且希望我們將其影印出來並帶往會場進行註冊。吾人攜帶這封 e-mail 影本前往會場，一進會場發現有一排電腦供與會者以紅外線掃描器掃描條碼進行登錄。接續印出個人名牌，往後必須攜帶這名牌才能在會場內行動，如果沒有攜帶名牌將會被強制驅離。印出名牌後則領取相關會議手冊，整個報到時間約 10 分鐘就完成，這報到的流暢度對於一個上萬人與會的場合令人激賞。此外此次大會亦有提供會議 APP 讓與會者攜帶手機或平板可以下載使用，這 APP 具有即時瞭解各討論會場地與各篇壁報摘要並可以已寄發訊息給與會學者等功用。在教育訓練會場，工作人員會發一個遙控器，上方有 1-4 的按鈕。當台上講者提出問題，並有數個選項希望台下與會者在 10 秒鐘內按下自己認為的答案，接續講者會公布會場內所有與會者的答案分布情況與正確答案。這系統可以讓台上講者瞭解台下與會者對於該主題的瞭解程度。
2. **全自動化微生物實驗室的趨勢:** 本次參與會議最重要的行程為想瞭解全自動化微生物實驗室目前相關進展與是否可行？在會場中亦可以看到廠商擺設出完整機台並且有專人進行講解，會議期間亦安排相關主題進行討論。但是，目前世界各地尚未有微生物實驗室採用。個人推測其主要原因可能有下列數點: 1. 全自動化微生物實驗室系統昂貴且尚不成熟穩定。2. 目前整合各機台間連結與臨床定義還有許多問題尚未解決。3. 工程人力需求增加，當採用這系統是否真的能夠減少人員工作量還是個謎。
3. **鮑氏不動桿菌治療的相關研究:** 本次會議中，個人對生物膜與抗毒力藥物的相關主題相當感興趣。有些專家在不同領域提出的想法相當有趣是以往個人研究中並未想到，吾人在回國後將仔細進行文獻搜尋，針對該主題有夠深入的瞭解，期望能應用於未來相關鮑氏不動桿菌相關研究主題。

最後為闕宗熙上校與孫俊仁針對本次會議心得提出相關建議:

1. **建議導入自助式報到系統讓研討會報到順暢:** 會議報到等流程順暢是值得我們以後辦理研討會參考，建議未來在舉辦相關研討會以可以比照讓與會者自行在單位印製出報到條碼標籤，接續前往會場採自助式報到。此一流程將可以減少辦理報到人力與會場報到時的紛亂情形。
2. **建議研討會會議議程 App 的提供以達無紙化理想:** 會議中有設計會議主題 App 可供下載，可以用行動裝置下載使用。內容為會議議程與所有發表論文之摘要。吾人建議軍醫大會也可以列用此模式設計 App，將可以減少紙張與光碟片的使用。
3. **全自動化微生物實驗室設計尚未成熟，建議持續關注:** 全自動化微生物實驗室的趨勢為本次會議中的重要噱頭且有具體儀器展出。但是，闕宗熙上校與孫俊仁經過相關學習與仔細評估現認為此系統目前尚未成熟，建議相關軍醫局與各軍醫院之微生物實驗室在現階段不需要對此系統抱持過多的期待。
4. **本次補助不足，建議未來能增加相關補助:** 本次闕宗熙上校與孫俊仁感謝獲得相關預算支持，出國參與國際會議。唯年度派員出國計畫預算有限，本年度補助方式為以壁報方式展示者給予機票費半額補助；生活費均不予補助。但是，國外生活花費甚鉅，本次約每人將自付約 8 萬元左右。因此建議未來如果經費預算充裕，相關人員參與國際會議可以獲得較多補助，藉此鼓勵軍職研究人員努力進行相關研究並且可以參與國際會議進行發表。

參、附件

附件一、24 屆歐洲臨床微生物及感染症大會(ECCMID)會議議程

Scientific Programme Overview

Saturday, 10 May 2014

| | Hall A | Hall B | Hall C | Hall D | Hall E |
|---------------|--|--|---|---|--|
| 8:45 | 08:45 – 12:45 EW10: Antimicrobial susceptibility testing with EUCAST breakpoints and methods | P.29 08:45 – 10:45 EW01: Infection prevention and management in long-term care facilities | P.29 08:45 – 10:45 EW02: Basic concepts of pharmacokinetics and pharmacodynamics | P.27 08:45 – 10:45 EW03: Tuberculosis and other mycobacterial infections in low-income countries | P.27 08:45 – 10:45 EW04: Vaccination in the elderly: perspectives |
| 10:00 | | | | | |
| 11:00 | | 11:00 – 13:00 EW11: Recent research in critically ill patients: hands-on evidence | P.29 11:00 – 13:00 EW12: Bloodstream infections: opportunities for outcome improvement | P.30 11:00 – 13:00 EW13: Basics of infections in travellers | P.30 11:00 – 13:00 EW14: Elderly and chronic hepatitis C – to treat or not to treat? |
| 12:00 | | | | | |
| 13:00 | | | | | |
| 13:30 – 15:30 | P.32 13:30 – 15:30 What's new in sepsis in 2014 | P.32 13:30 – 15:30 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 316 for details | 13:30 – 15:30 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 316 for details | P.32 13:30 – 15:30 Uncertainties in transplant vaccination | P.32 13:30 – 15:30 Lessons learned from <i>Clostridium difficile</i> molecular epidemiology |
| 14:00 | | | | | |
| 15:00 | | | | | |
| 16:00 | | | | | |
| 16:30 – 18:30 | P.34 16:30 – 18:30 Implementing international guidelines to reduce the spread of MDR Gram-negatives at national level | P.34 16:30 – 18:30 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 317 for details | 16:30 – 18:30 The Good, the Bad and the Ugly: recently approved and developmental anti-bacterials | P.35 16:30 – 18:30 New insights in epidemiology, resistance and pathogenesis to improve HIV management | P.35 16:30 – 18:30 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 317 for details |
| 17:00 | | | | | |
| 18:00 | | | | | |
| 19:00 | 19:00 – 22:00 Opening Ceremony followed by Networking Reception | | | | |

Sunday, 11 May 2014

| | Hall A | Hall B | Hall C | Hall D | Hall E |
|---------------|--|--|--|--|--|
| 7:45 | 07:45 – 08:45 Sepsis management beyond antibiotics | P.39 | | P.39 07:45 – 08:45, Outbreak of <i>P. aeruginosa</i> in your hospital and you think it could be water-related? Want to know what to do next? | |
| 8:00 | | | | | |
| 9:00 | 09:00 – 11:00 What is new on surgical site infection prevention? | P.39 09:00 – 11:00 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 319 for details | 09:00 – 11:00 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 319 for details | P.40 09:00 – 11:00 Monitoring antibiotic use | P.40 09:00 – 11:00 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 320 for details |
| 10:00 | | | | | |
| 11:00 | | | | | |
| 11:30 – 12:30 | P.42 11:30 – 12:30 Deep insights in mycobacteria: genomics and susceptibility | P.43 11:30 – 12:30 Genomic diagnostics: transforming clinical and public health microbiology practice | P.43 11:30 – 12:30 Macrolides are still safe and effective to be used in clinical practice. Pro / Con debate | P.43 11:30 – 12:30 Great scientific success with scarce resources, is money issue a crucial point? | P.43 11:30 – 12:30 Emergence of <i>Clostridium difficile</i> infections outside healthcare facilities |
| 12:00 | | | | | |
| 13:00 | | | 13:00 – 14:00: EPOSTER & POSTER VIEWING | P.77 13:00 – 14:00 ePoster Session: Post-surgical and implant infections: from head to knee | |
| 14:00 | | | | | |
| 14:30 – 15:30 | P.45 14:30 – 15:30 The year in Infection Control | P.46 14:30 – 15:30 Hepatitis B treatment and management | P.46 14:30 – 15:30 Knowledge and social norms shaping the discovery, use, and resistance trends of antimicrobial agents | P.46 14:30 – 15:30 Training in Infection in Europe – progress in curricula and assessments | P.46 14:30 – 15:30 <i>Listeria</i> and listeriosis |
| 15:00 | | | | | |
| 16:00 | P.48 16:00 – 18:00 Improving empirical antibiotic treatment in hospital | P.48 16:00 – 18:00 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 321 for details | 16:00 – 18:00 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 321 for details | P.48 16:00 – 18:00 Use of next generation sequencing in clinical practice | P.49 16:00 – 18:00 Making sense of our relationships with mucosal commensals and pathogens |
| 17:00 | | | | | |
| 18:00 | | | | | |

Meet-the-Expert Sessions 2-hour Symposia
1-hour Symposia Keynote Lectures 1-hour Oral Sessions
2-hour Oral Sessions
ePoster & Poster Sessions Integrated Symposia

Saturday, 10 May 2014

| Hall F | Hall G | Hall H | Hall I | Hall J | Hall 132/133 | Registration, Exhibition, Posters |
|--|---|---|---|---|---|---|
| 08:45 – 10:45 EW05: Tick-borne diseases prevalent in Europe | P.28 08:45 – 10:45 EW06: Diagnosis and treatment of <i>Helicobacter pylori</i> infection. What is new in 2014? | P.28 08:45 – 10:45 EW07: Viral infections in pregnancy | P.28 08:45 – 10:45 EW08: Management of ocular parasitic diseases | P.28 08:45 – 10:45 EW09: How to diagnose and treat bacterial and fungal biofilm infections | P.29 | Registration 07:00 – 18:30 Exhibition 12:00 – 18:45 Posters 15:30 – 16:30 Session I ePosters Viewing Throughout congress hours |
| 11:00 – 13:00 EW15: When is a food-borne infection not a food-borne infection? | P.30 11:00 – 13:00 EW16: Update on anaerobes: new methods bring new information about the bugs and their importance in health and disease | P.31 11:00 – 13:00 EW17: How to prevent the consequences of EBV infection in transplant recipients? | P.31 11:00 – 13:00 EW18: Human parasites of the gut: epidemiology and diagnostic approaches in the molecular era | P.31 11:00 – 13:00 EW19: ESCMID guidelines for diagnosis and treatment of <i>Aspergillus</i> diseases | P.31 | |
| 13:30 – 15:30 P.33 Ticks and tick-borne pathogens | 13:30 – 15:30 P.33 Improving antibiotic prescription quality | 13:30 – 15:30 P.33 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 316 for details | 13:30 – 15:30 P.34 Application of new methods in medical microbiology and infection control | 13:30 – 15:30 P.34 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 316 for details | 13:30 – 16:45 P.34 TAE Trainees Day | |
| 16:30 – 18:30 P.36 Epidemiology based on whole genome sequencing | 16:30 – 18:30 P.36 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 317 for details | 16:30 – 18:30 P.36 Laboratory response to emerging viral diseases: from pathogen discovery to disease monitoring | 16:30 – 18:30 P.36 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 318 for details | 16:30 – 18:30 P.37 Carbenemases from prevention to treatment | P.37 | |

Sunday, 11 May 2014

| Hall F | Hall G | Hall H | Hall I | Hall J | Registration, Exhibition, Posters |
|---|---|--|---|---|---|
| 07:45 – 08:45 P.39 Addressing the problem of MDR <i>Neisseria gonorrhoeae</i> | | 07:45 – 08:45 P.39 Controversies in treatment of malaria and crismean-congo haemorrhagic fever | 07:45 – 08:45 P.39 Screening for carbapenemase production, molecular and phenotypic methods | P.39 07:45 – 08:45 P.39 New viruses: pathogens or innocent bystanders? | Registration 07:00 – 18:00 Exhibition 09:00 – 17:30 Posters 12:30 – 13:30 Session II 13:30 – 14:30 Session III ePosters Viewing Throughout congress hours |
| 09:00 – 11:00 P.40 Exploring and treating biofilms | 09:00 – 11:00 P.40 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 320 for details | 09:00 – 11:00 P.41 News in travel, tropical and parasitic infections | 09:00 – 11:00 P.41 MALDI-TOF mass spectrometry: ongoing revolution in clinical microbiology | 09:00 – 11:00 P.42 Basic science: pathogenesis and epidemiology of Gram-positive bacteria | |
| 11:30 – 12:30 P.44 Automation in diagnostic bacteriology | P.44 11:30 – 12:30 P.44 MDR <i>Acinetobacter baumannii</i> | P.44 11:30 – 12:30 P.44 The great filter: parasitic infections of the liver | 11:30 – 12:30 P.44 Emerging resistance in fungi | P.45 11:30 – 12:30 P.45 Viral opportunists in the critically ill patient | |
| 13:00 – 14:00 P.77 ePoster Session: PK/PD to improve treatment of critically ill patients | 13:00 – 14:00 P.77 ePoster Session: Microbiome and resistance: what are they telling us? | 13:00 – 14:00 P.78 ePoster Session: STD and other genital infections | 13:00 – 14:00 P.79 ePoster Session: Antifungal drug susceptibility and resistance | P.79 | |
| 14:30 – 15:30 P.46 Why are some carbapenemases successful? | P.46 14:30 – 15:30 P.46 Microbiome and microbiota: new "M"s in microbiology | P.47 14:30 – 15:30 P.47 An update on malaria | P.47 14:30 – 15:30 P.47 Different prevention strategies in immunocompromised patients | P.48 14:30 – 15:30 P.48 Hot topic: Ebola in Africa | |
| 16:00 – 18:00 P.50 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 322 for details | 16:00 – 18:00 P.50 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 322 for details | 16:00 – 18:00 P.50 Ins and outs of Legionnaires disease | 16:00 – 18:00 P.50 Infections and devices: imaging & nuclear medicine meets infectious diseases | P.50 16:00 – 18:00 P.50 Bacterial persistence and tolerance: from bench to bedside | |

Scientific Programme Overview

Monday, 12 May 2014

| | HALL A | HALL B | HALL C | HALL D | HALL E |
|-------|---|--|---|---|--|
| 7:45 | | | | | |
| 8:00 | 07:45 – 08:45 The management of HIV/HCV infection in the era of direct active drugs P 51 | | | 07:45 – 08:45 EUCAST questions and answers P 51 | |
| 9:00 | 09:00 – 11:00 What is hot in HIV in 2014? P 51 | 09:00 – 11:00 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 323 for details | 09:00 – 11:00 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 323 for details | 09:00 – 11:00 Colistin: position in the era of multi-resistance P 52 | 09:00 – 11:00 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 324 for details |
| 10:00 | | | | | |
| 11:00 | | | | | |
| 11:30 | 11:30 – 12:30 Better to prevent than to cure: case of HIV P 53 | 11:30 – 12:30 Molecular diagnosis: commercial or home-made tests – Pro / Con debate P 53 | 11:30 – 12:30 Fighting against fungal infections: cells on the front lines P 54 | 11:30 – 12:30 Antibundance drugs P 54 | 11:30 – 12:30 Enterococcal resistance P 54 |
| 12:00 | | | | | |
| 13:00 | 13:00 – 14:00: ePoster & Poster viewing | | | 13:00 – 14:00 ePoster Session: Antibacterial drug activity and interactions in Gram-positive organisms P 81 | |
| 14:00 | | | | | |
| 14:30 | 14:30 – 15:30 HIV – behaviour and beliefs P 56 | 14:30 – 15:30 Going away from blood: why not to test oral fluid and urine? P 56 | 14:30 – 15:30 Excellence Award Lecture: Close encounters of the third kind – pathogens and globalisation P 57 | 14:30 – 15:30 New antibiotics in clinical trials P 57 | 14:30 – 15:30 T-cells in invasive aspergillosis P 57 |
| 15:00 | | | | | |
| 16:00 | 16:00 – 18:00 Cryptococcal infections in HIV infected patients: what is new in 2014? P 59 | 16:00 – 18:00 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 325 for details | 16:00 – 18:00 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 325 for details | 16:00 – 18:00 New transmission routes and genotypic diversity: are we looking at a new MRSA? P 59 | 16:00 – 18:00 Predicting the future in fungal diagnosis and therapy P 60 |
| 17:00 | | | | | |
| 18:00 | | | | | |

Tuesday, 13 May 2014

| | Hall A | Hall B | Hall C | Hall D | Hall E |
|-------|---|---|--|--|--|
| 7:45 | | | | | |
| 8:00 | | 07:45 – 08:45 How to use next generation sequencing in future virology P 63 | 07:45 – 08:45 Control of vancomycin-resistant enterococci: efforts justified? P 63 | 07:45 – 08:45 Management and troubleshooting of in-house molecular diagnostics in the microbiological lab P 63 | 07:45 – 08:45 Antimicrobial resistance research, supported by funding from the EU and the US NIH/NIAD P 63 |
| 9:00 | 09:00 – 11:00 Clinical Grand Round 2014 P 64 | 09:00 – 11:00 The challenge of respiratory viruses P 64 | 09:00 – 11:00 What is new in immunocompromised patients? P 64 | 09:00 – 11:00 Nebulised antibiotics: challenge for 2014 P 65 | 09:00 – 11:00 Combined antimicrobial therapy for multi-resistant Gram-negative bacteria P 65 |
| 10:00 | | | | | |
| 11:00 | | | | | |
| 11:30 | 11:30 – 12:30 The year in Clinical Microbiology P 67 | 11:30 – 12:30 Cross-neutralising antibodies for respiratory virus therapy and vaccine design P 67 | 11:30 – 12:30 Surveillance of healthcare-associated infections: infections or procedures? P 68 | 11:30 – 12:30 Advances in CMV infection in transplant recipients P 68 | 11:30 – 12:30 Young Investigator Award Lectures P 69 |
| 12:00 | | | | | |
| 13:00 | ePoster & Poster Viewing | | | | |
| 13:30 | 13:30 – 15:30 Controlling transmission of multidrug-resistant pathogens in the intensive care unit P 70 | 13:30 – 15:30 Hot topics in vaccine-preventable diseases P 70 | 13:30 – 15:30 Antimicrobial prophylaxis of surgical site infections: time to review? P 70 | 13:30 – 15:30 Emerging infectious diseases P 71 | 13:30 – 15:30 Case-based decisions in the era of XDR Gram-negatives: towards individualised therapy? P 71 |
| 14:00 | | | | | |
| 15:00 | | | | | |
| 15:15 | | | | | |
| 15:30 | | | | | |

Meet the Expert Sessions 2-hour Symposia
1-hour Symposia Keynote Lectures 1-hour Oral Sessions
2-hour Oral Sessions ePoster & Poster Sessions Integrated Symposia

Monday, 12 May 2014

| HALL F | HALL G | HALL H | HALL I | HALL J | Registration, Exhibition, Posters |
|---|---|---|---|--|---|
| 07:45 – 08:45 P. 51 New nomenclature: new species – any realising clinical relevance? | | 07:45 – 08:45 P. 51 Altered drug disposition in the elderly | 07:45 – 08:45 P. 51 Who should and who should not receive drug treatment for Chagas disease? | 07:45 – 08:45 P. 51 Current challenges and emerging evidence of infection control and prevention measures in long-term care facilities | Registration 07:00 – 18:00 Exhibition 09:00 – 17:30 |
| 09:00 – 11:00 P. 52 Full laboratory automation | 09:00 – 11:00 P. 52 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 324 for details. | 09:00 – 11:00 P. 52 Outbreaks of MDR Gram-negative bacteria: what works and what does not work? | 09:00 – 11:00 P. 52 An update on leishmaniasis | 09:00 – 11:00 P. 53 Staphylococcus aureus bacteraemia: controversial issues | Posters 12:30 – 13:30 Session IV 13:30 – 14:30 Session V ePosters Viewing Throughout congress hours |
| 11:30 – 12:30 P. 55 Molecular detection of resistance: dream or reality? | 11:30 – 12:30 P. 55 Community-acquired pneumonia – current challenges and future directions | 11:30 – 12:30 P. 55 Viral paediatric infections | 11:30 – 12:30 P. 55 Acute anaemia after treatment of malaria with intravenous artesunate – a new variant of "blackwater fever"? | 11:30 – 12:30 P. 56 The year in Infectious Diseases | |
| 13:00 – 14:00 P. 82 ePoster Session: Assessing and decreasing environmental contamination | 13:00 – 14:00 P. 82 ePoster Session: Community-acquired pneumonia | 13:00 – 14:00 P. 83 ePoster Session: Vaccine development | 13:00 – 14:00 P. 84 ePoster Session: Highlights from molecular mycology | 13:00 – 14:00 P. 85 ePoster Session: Highlights from molecular mycology | |
| 14:30 – 15:30 P. 57 The effects of antibiotic pollution on the environmental resistance gene reservoir | 14:30 – 15:30 P. 57 Detection of broad-spectrum beta-lactamases | 14:30 – 15:30 P. 57 Viral diagnostics in the immunocompromised | 14:30 – 15:30 P. 58 Diagnostic tools in parasitology | 14:30 – 15:30 P. 58 On the cutting edge of infection control research: what to do when evidence is missing? | |
| 16:00 – 18:00 P. 60 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 326 for details. | 16:00 – 18:00 P. 60 Forensic and post-mortem microbiology in the 21st century | 16:00 – 18:00 P. 60 New approaches to prevent transmission of Clostridium difficile infections | 16:00 – 18:00 P. 60 Non-molecular diagnosis of central nervous system and bloodstream infections | 16:00 – 18:00 P. 60 Integrated Symposium [not included in main event CME/CPD credit] Refer to page 326 for details. | |

Tuesday, 13 May 2014

| HALL F | HALL G | HALL H | HALL I | HALL J | Registration, Exhibition, Posters |
|---|--|---|--|--|--|
| 07:45 – 08:45 P. 63 Strategies for malaria prevention, why do national guidelines differ? | 07:45 – 08:45 P. 63 Healthcare providers and influenza vaccination | | 07:45 – 08:45 P. 63 How to treat MDR tuberculosis? | | Registration 07:00 – 15:30 Exhibition 09:00 – 15:30 |
| 09:00 – 11:00 P. 65 Healthcare-associated infections – from analysis to interventions | 09:00 – 11:00 P. 65 Bacterial paediatric infections | 09:00 – 11:00 P. 66 PK/PD – the merits of models and measurement | 09:00 – 11:00 P. 67 The hidden Beijing M. tuberculosis pandemic | 09:00 – 11:00 P. 67 Optimisation of empirical and targeted antifungal therapy for invasive aspergillosis | Posters 12:30 – 13:30 Session VI ePosters Viewing Throughout congress hours |
| 11:30 – 12:30 P. 69 Advances in molecular mycology: notes from the bench | | 11:30 – 12:30 P. 69 Can we treat Gram-negative bacteraemia with a short-course of antibiotics? Pro / Con debate | 11:30 – 12:30 P. 69 Mycobacteria in cutaneous infections | 11:30 – 12:30 P. 69 HIV and hepatitis C co-infection: double trouble? | |
| 13:30 – 15:30 P. 72 Clinical mycology update 2014 | 13:30 – 15:30 P. 72 New old antibiotics: safety and efficacy | 13:30 – 15:30 P. 73 Improving treatment of severe infections | 13:30 – 15:30 P. 74 Two-faced companions: highlights in the world of anaerobes | 13:30 – 15:30 P. 75 PCR and other molecular tests directly on blood: what is new? | |

附件二、與會人員與 ECCMID 陳設之中華民國國旗合照。

- 關宗熙主任與 ECCMID 會場擺設國旗合照



- 孫俊仁 與 ECCMID 會場擺設國旗合照




附件三、與會人員與三總在本次 ECCMID 會場發表之電子壁報合照。

- 關宗熙主任與其所發表之電子壁報合照 (編號為 eP508)



- 孫俊仁 與其所發表之電子壁報合照 (編號為 eP508)



附件四、關宗熙主任與孫俊仁發表壁報列於大會手冊。關宗熙主任發表主題為「AdeR protein regulates AdeABC expression by binding to direct-repeat motif in the intergenic spacer」，編號為 eP509。孫俊仁發表主題為「Verification of the amino acid substitutions in adeRS for tigecycline resistance in clinical isolates of the extensively drug resistant *Acinetobacter baumannii*」，編號為 eP508。

| ePoster Viewing | |
|---|--|
| Saturday, 10 May 2014 - Tuesday, 13 May 2014 | |
| <p>eP501 Human microbiota biobank (HUMB) at University of Tartu, Estonia <i>T. Rööp*</i> (Tartu, Estonia), <i>H. Mändar, M. Mikelsaar, R. Mändar</i></p> | <p>eP509 AdeR protein regulates AdeABC expression by binding to a direct-repeat motif in the intergenic spacer <i>T.S. Chiueh*</i> (Taipei, Taiwan), <i>B.J. Huang, T.Y. Chang, J.R. Sun, C.L. Perng</i></p> |
| <p>eP502 Searching for peritonitis-causing agents in the normal microbiota of peritoneal dialysis patients: analysis of possible routes of infection <i>L. Simões Silva*</i> (Porto, Portugal), <i>S. Ferreira, S. Silva, R. Araujo, M.J. Sousa, C. Santos-Araújo, M. Pestana, I. Soares-Silva, B. Sampaio-Maia</i></p> | <p>eP510 Fitness cost of fluoroquinolone resistance in <i>Acinetobacter baumannii</i> mediated through a combination of <i>gyrA/parC</i> mutations and efflux <i>J. Nowak*</i> (Cologne, Germany), <i>H. Seifert, P.G. Higgins</i></p> |
| Viewing Stations | |
| EPOSTER VIEWING: MDR <i>Acinetobacter baumannii</i> | |
| <p>eP503 Large dissemination of <i>bla</i>OXA-58 and <i>bla</i>OXA-23 carbapenemase genes of <i>Acinetobacter baumannii</i> in a Tunisian neonatal intensive care unit <i>A. Mabrouk, W. Achour*</i> (Tunis, Tunisia), <i>S. Ennigrou, R. Baaboura, A. Ben Hassen</i></p> | <p>eP511 Relevance of microbiological aspects in the results of the first year of a multidisciplinary sepsis unit in a teaching hospital <i>J. Camarena*</i> (Valencia, Spain), <i>R. Gonzalez, B. Bonet, S. Sancho, R. Zaragoza, J.M. Nogueira</i></p> |
| <p>eP504 Carbapenem resistance molecular determinants in nosocomial isolates of multidrug-resistant <i>Acinetobacter baumannii</i> in Tehran Hospital, Iran <i>A. Karmostaji*</i> (Bandar-Abbas, Iran), <i>S. Najar Peerayeh, P. Davoodian, S. Javadpour</i></p> | <p>eP512 International antimicrobial stewardship pharmacist mentoring programme: united we stand, divided we fall <i>D.A. Goff*</i> (Columbus, United States), <i>K. Bauer, D. Van den Bergh, A. Brink, J. Taljaard, M. Mendelson</i></p> |
| <p>eP505 First report of ISAb825 upstream of <i>bla</i>OXA-143 gene in carbapenem-resistant <i>Acinetobacter baumannii</i> (ACB) clinical isolates <i>R. Cayô*</i> (São Paulo, Brazil), <i>A.P. Motos, F. Rodrigues-Costa, R. Girardello, C.G. Carvalhaes, A.C. Gales</i></p> | <p>eP513 Results of a stewardship programme for the management of <i>S. aureus</i> bacteraemia <i>J. Boelens*</i> (Ghent, Belgium), <i>I. Leroux-Roels, S. Callens, F. Buyle, D. Vogelaers, On behalf of the Multidisciplinary Infection Team</i></p> |
| <p>eP506 OXA-253, a variant of the carbapenem-hydrolysing class D beta-lactamase OXA-143 in <i>Acinetobacter baumannii</i> <i>D. Girlich*</i> (Le Kremlin Bicêtre, France), <i>Q. Damaceno, A.C. Oliveira, P. Nordmann</i></p> | <p>eP514 Promoting the appropriateness of antibiotic prescribing and decreasing the parenteral antibiotic prescribing amount by an effective multidimensional antibiotic stewardship programme <i>W. Wang*</i> (Taichung, Taiwan), <i>C. Huang, S. Chou, Y. Huang, S. Chan</i></p> |
| <p>eP507 Effect of the acquisition of reduced susceptibility to biocides on the expression of genes encoding porins and efflux pumps in <i>Acinetobacter baumannii</i> <i>F. Fernández-Cuenca*</i> (Seville, Spain), <i>P. Egea, M. Tomás-Carmona, G. Bau, L. Martínez-Martínez, J. Vila, J. Pachón, J.M. Cisneros, J. Rodríguez-Baño, A. Pascual</i></p> | <p>eP515 Outcome of implementation of antimicrobial review notice stickers and care bundle in a large district general hospital in the east of England <i>T. Vaghela*</i> (Watford, United Kingdom), <i>A. Flatt, S. Parida, R. Wiggins, P. Seetulsingh</i></p> |
| <p>eP508 Verification of the amino acid substitutions in <i>adeRS</i> for increasing tigecycline resistance in clinical isolates of the extensively drug resistant <i>Acinetobacter baumannii</i> <i>J.R. Sun*</i> (Taipei, Taiwan), <i>T.S. Chiueh</i></p> | <p>eP516 Evaluation of active interventions for bloodstream infections in a Japanese university hospital <i>M. Nagao*</i> (Kyoto, Japan), <i>G. Hotta, K. Kato, S. Nakano, T. Yunoki, M. Yamamoto, Y. Matsumura, Y. Ito, S. Takakura, S. Ichiyama</i></p> |
| 24th ECCMID / Barcelona Final Programme 119 | |

附件五、全自動化微生物實驗室。(圖片取自 J Clin Microbiol. Jun 2013; 51(6): 1658 - 1665.)

- Kiestra TLA system



- FMLA system



- WASPLab



附件六、Kiestra TLA system 全自動化微生物實驗室陳設於 ECCMID 會場。

- 培養皿傳送軌道系統



- 檢體自動接種與塗抹系統



- 培養皿影像自動判讀系統



- 培養皿培養溫箱

